Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 21Uterine Cervical Neoplasms 15Esophageal Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Vaginal Neoplasms 2Rhabdomyosarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Melanoma 2Uveal Melanoma 1Uterine Neoplasms 1Sarcoma 1Retinoblastoma 1Recurrent Head and Neck Carcinoma 1Prostatic Diseases 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Malignant Female Reproductive System Neoplasm 1Lung Neoplasms 1Locally Advanced Cervical Adenocarcinoma 1Gynecologic Cancer 1Esophageal Squamous Cell Carcinoma 1Endometrial Clear Cell Adenocarcinoma 1Desmoplastic Small Round Cell Tumor 1Cervical Adenocarcinoma 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1

Interventions

tremelimumab 1durvalumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Immunoglobulin G 1Disulfides 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Malignant Female Reproductive System Neoplasm × Brachytherapy × 1 year × Clear all
NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
9 enrolled

Metastatic Malignant Female Reproductive System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡